A study to record the effects of intense exercise in people with prostate cancer is carried out in an international clinical trial. One of the researchers, Dr.Fred Saad, urologist-oncologist at University Hospital Research Center in Montreal (CRCHUM) says that exercise can have a healing effect on cancer as much as drugs, even in patients in advanced stages of cancer prostate.
Dr. Fred Saad, along with Robert Newton, a professor at the Research Institute of Exercise Medicine of Edith Cowan University in Australia, is carrying out an international study, which focuses on the benefits of exercise in people with metastatic cancer.
With the progression of the disease, patients tend to become sedentary, contributing to the worsening of the condition. Researchers have found that exercise can literally extend the life of a person for a couple of years with prostate cancer.
Patients in the advanced stage of live 2-3 years more and researchers have been trying to reduce mortality by 22% at least, which means that patients will be able to live a six months. This is equivalent to the effects of new drugs. Therefore, Dr. Saad concluded that exercise could be considered as a powerful adjunct to medications and treatments.
The study has already begun in Australia and Ireland. Within a few weeks to about 60 hospitals around the world they will be involved in the study, recruiting 900 men in advanced stages of prostate cancer.
Saad confirmed that all participants will be treated with advanced medical instruments and methods. The exercise will be carried out as a treatment with standard procedures.
A specialist will monitor the patients in the “exercise group ‘for 12 months. Program cardiovascular and strength training, along with resistance training and aerobics three times a week exercises have been in your plan treatment.
the result will be analyzed in terms of improvement in life, tolerance of treatment and appetite in relation to their physical condition.
researchers have hypothesized that the exercise has a clear connection with the progression of the disease and leads to an extension of the useful life while helping patients tolerate therapy treatments better.
Dr. Saad is ready to present his research in the third phase of the clinical trial at the annual conference of the American Society of clinical Oncology (ASCO), from 3 to 7 June in Chicago.